| Issuer | % of Class | Filed |
|---|---|---|
|
ADARx Pharmaceuticals, Inc.
13G
ADRX · 00654F105
|
6.3% |
10/1/2026
Event 9/24/2026
|
|
Heartflow, Inc.
13G/A
Amendment 2
HTFL · 42238D107
|
9.8% |
8/14/2026
Event 6/30/2026
|
|
Heartflow, Inc.
13G/A
Amendment 1
HTFL · 42238D107
|
12.2% |
5/15/2026
Event 3/31/2026
|
|
Cidara Therapeutics, Inc.
13G/A
Amendment 3
CDTX · 171757206
|
0% |
2/17/2026
Event 12/31/2025
|
|
Dianthus Therapeutics, Inc.
13G/A
Amendment 3
DNTH · 252828108
|
3.1% |
11/14/2025
Event 9/30/2025
|
|
Cidara Therapeutics, Inc.
13G/A
Amendment 2
CDTX · 171757206
|
10.0% |
11/14/2025
Event 9/30/2025
|
|
Heartflow, Inc.
13G
HTFL · 42238D107
|
14.9% |
11/14/2025
Event 9/30/2025
|
|
Dianthus Therapeutics, Inc.
13G/A
Amendment 2
DNTH · 252828108
|
7.5% |
8/14/2025
Event 6/30/2025
|
|
Cidara Therapeutics, Inc.
13G/A
Amendment 1
CDTX · 171757206
|
10.0% |
8/14/2025
Event 6/30/2025
|
|
Dianthus Therapeutics, Inc.
13G/A
Amendment 1
DNTH · 252828108
|
8.8% |
2/14/2025
Event 12/31/2024
|
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.